RxDoctor Payments Data

Tracy Hildebran

Nurse Practitioner · Salisbury, NCNPI 1023094661

Payments from drug & device makers

$3,503in general payments, 2019–2025

Across 107 payments — averaging $32.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$639
  • Novo Nordisk$554
  • AbbVie$529
  • Astellas Pharma US Inc$255
  • Lilly USA, LLC$249
  • Exact Sciences$245
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,35796%
  • Education$1464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,503 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$90,384
Medicare patients
177
Services billed
2,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab14$97,351
EliquisApixaban74$62,471
OzempicSemaglutide41$54,317
MounjaroTirzepatide49$46,091
JardianceEmpagliflozin43$28,677
JanuviaSitagliptin Phosphate23$17,686
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$17,192
TrulicityDulaglutide17$17,035
TradjentaLinagliptin11$16,584
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$14,146
Repatha SureclickEvolocumab18$10,081
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$6,708
SymbicortBudesonide/Formoterol Fumarate21$6,310
SynthroidLevothyroxine Sodium63$5,547
ShingrixVaricella-Zoster Ge/As01b/Pf21$4,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$184$68,254101 claims
Lilly USA, LLCMounjaro, Trulicity$249$63,12666 claims
Novo NordiskOzempic$554$54,31741 claims
GSKTrelegy Ellipta, Shingrix$32$21,92340 claims
MerckJanuvia$15$17,68623 claims
AstraZenecaSymbicort$639$6,31021 claims
AbbVieSynthroid$529$5,54763 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$26$3,302315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Salisbury

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →